End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.69 CNY | -1.22% | -5.61% | -27.08% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Construction & Engineering
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.08% | 276M | - | ||
+0.70% | 71.52B | C+ | ||
+3.69% | 60.37B | C+ | ||
+31.91% | 41.49B | B+ | ||
+18.09% | 33.04B | B | ||
+10.54% | 29.16B | A- | ||
+18.31% | 21.68B | B- | ||
+11.86% | 19.14B | A | ||
+83.47% | 18.74B | B | ||
+37.36% | 17.46B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301235 Stock
- Ratings Wuhan Huakang Century Medical Co., Ltd.